Education
About Us
Working with TipRanks
Follow Us
Eyenovia (EYEN)
:EYEN
EYEN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.06 - $124.80
Previous CloseN/A
Volume25.52M
Average Volume (3M)401.97K
Market Cap
$2.33M
Enterprise Value$41.79M
Total Cash (Recent Filing)-$3.39M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.33
Next Earnings
May 14, 2025EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-58.50
Shares Outstanding2,100,000
10 Day Avg. Volume965,842
30 Day Avg. Volume401,966
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)91.04
Price to Cash Flow (P/CF)-0.10
P/FCF Ratio0.00
Enterprise Value/Market Cap17.93
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.22
Forecast
1Y Price Target
$2.00Price Target Upside80.18% Upside
Rating ConsensusHold
Number of Analyst Covering1
---
Bulls Say, Bears Say
Bulls Say
FDA ApprovalsEyenovia retains two FDA approvals for its Optejet delivery system, enhancing its credibility and potential market presence.
Market ExpansionEyenovia's efforts to pursue an additional 200 active practices build on the current 230 offices for Mydcombi adoption, signaling potential expansion and increased market penetration.
Mergers And PartnershipsThe proposed merger of topical ophthalmic platforms could present the next constructive chapter for Optejet and broader development.
Bears Say
Analyst RatingThe rating for Eyenovia has been changed to Neutral from Buy, reflecting a more cautious outlook.
Clinical Trial ChallengesThe Phase 3 CHAPERONE study did not meet its primary endpoint for pediatric myopia, leading to the discontinuation of the MicroPine study.
Investment RisksRisks to the investment thesis include failure of products and/or candidates to achieve peak commercial revenue estimates due to market size, penetration rates, and/or pricing.
---
Ownership Overview
11.34% Insiders
2.29% Mutual Funds
9.00% Other Institutional Investors
75.71% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
EYEN FAQ
What was Eyenovia’s price range in the past 12 months?
Eyenovia lowest stock price was $1.06 and its highest was $124.80 in the past 12 months.
What is Eyenovia’s market cap?
Eyenovia’s market cap is $2.33M.
When is Eyenovia’s upcoming earnings report date?
Eyenovia’s upcoming earnings report date is May 14, 2025 which is in 39 days.
How were Eyenovia’s earnings last quarter?
Eyenovia released its earnings results on Mar 26, 2025. The company reported -$0.1 earnings per share for the quarter, the consensus estimate of -$0.1 by $0.
Is Eyenovia overvalued?
According to Wall Street analysts Eyenovia’s price is currently Undervalued.
Does Eyenovia pay dividends?
Eyenovia does not currently pay dividends.
What is Eyenovia’s EPS estimate?
Eyenovia’s EPS estimate is -0.1.
How many shares outstanding does Eyenovia have?
Eyenovia has 2,100,000 shares outstanding.
What happened to Eyenovia’s price movement after its last earnings report?
Eyenovia reported an EPS of -$0.1 in its last earnings report, expectations of -$0.1. Following the earnings report the stock price went down -5.263%.
Which hedge fund is a major shareholder of Eyenovia?
Currently, no hedge funds are holding shares in EYEN
---
Company Description
Eyenovia
Eyenovia, Inc. (EYEN) is a clinical stage biopharmaceutical company focused on developing a pipeline of ophthalmology products leveraging its proprietary microdose array print (MAP) technology. Based in the United States, Eyenovia aims to transform the delivery of therapeutics for eye diseases such as myopia and presbyopia by improving precision and reducing side effects associated with traditional eye drop formulations.
---
EYEN Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed outlook with significant advances in product development and strategic partnerships but was overshadowed by financial challenges and a need for further capital. The company is making strong progress in product launches and regulatory approvals but faces ongoing financial hurdles that need addressing.Read More>---
EYEN Stock 12 Month Forecast
Average Price Target
$2.00
▲(80.18% Upside)
Technical Analysis
EyePoint Pharmaceuticals
―
Aldeyra Therapeutics
―
Ocular Therapeutix
―
Ocugen
―
Kala Pharmaceuticals
―
---